Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH
Prepubertal antiandrogen, aromatase inhibitor combination with reduced hydrocortisone improves short-term predicted height for children with CAH but does not result in taller adult stature than those treated with standard therapy, and is not recommended. Females may benefit from antiandrogen treatment during puberty.
Authors
- Megan Parker (ORCID: https://orcid.org/0000-0002-1096-9662)
- Ashwini Mallappa (ORCID: https://orcid.org/0000-0003-0637-4559)
- Deborah P. Merke (ORCID: https://orcid.org/0000-0002-3746-0460)
- James C. Reynolds (ORCID: https://orcid.org/0000-0003-1176-3030)
- Margaret F. Keil (ORCID: https://orcid.org/0000-0001-5077-2218)
- Carol Van Ryzin
- Ninet Sinaii (ORCID: https://orcid.org/0000-0003-4045-1386)
- Charles Sukin (ORCID: https://orcid.org/0009-0009-5105-4475)
- Suvimol Hill
- Gordon B. Cutler (ORCID: https://orcid.org/0000-0001-8925-5728)
- Shruti N. Kulkarni (ORCID: https://orcid.org/0009-0002-0495-0532)
Institutions
- National Institutes of Health (US)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
- National Institutes of Health Clinical Center (US)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1210/clinem/dgae824
- Citations
- 5
- Primary Topic
- Sexual Differentiation and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development